within Pharmacolibrary.Drugs.ATC.G;

model G03EA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03EA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methyltestosterone and estrogen combination is a hormonal preparation historically used in hormone replacement therapy (HRT) for postmenopausal symptoms. Methyltestosterone is a synthetic androgen, while estrogen (commonly as conjugated estrogens or estradiol) serves as female sex hormone replacement. This combination is rarely used today due to concerns about adverse effects and availability of safer alternatives. In many countries, such fixed combinations are not currently approved.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic studies reporting population PK parameters for the fixed combination of methyltestosterone and estrogen with ATC code G03EA01 are available in published literature. Below are estimated parameters based on known individual PK properties of methyltestosterone and oral estrogens in healthy adult women.</p><h4>References</h4><ol><li><p>Simon, J, et al., &amp; Yang, HM (1999). Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. <i>Menopause (New York, N.Y.)</i> 6(2) 138–146. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10374221/\">https://pubmed.ncbi.nlm.nih.gov/10374221</a></p></li><li><p>Fabian, E, et al., &amp; Landsiedel, R (2019). In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds. <i>Archives of toxicology</i> 93(2) 401–416. DOI:<a href=\"https://doi.org/10.1007/s00204-018-2372-z\">10.1007/s00204-018-2372-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30552464/\">https://pubmed.ncbi.nlm.nih.gov/30552464</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03EA01;
